TherapeuticsMD has been granted a patent for progesterone formulations that allow for reduced dosage while maintaining efficacy. The pharmaceutical composition includes progesterone, a solubilizing agent, and a nonionic surfactant, offering potential benefits for patients in need. GlobalData’s report on TherapeuticsMD gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights TherapeuticsMD Inc

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on TherapeuticsMD, Telomerase reverse transcriptase screening was a key innovation area identified from patents. TherapeuticsMD's grant share as of February 2024 was 78%. Grant share is based on the ratio of number of grants to total number of patents.

Progesterone formulation for oral administration with reduced dosage

Source: United States Patent and Trademark Office (USPTO). Credit: TherapeuticsMD Inc

A recently granted patent (Publication Number: US11865179B2) discloses a pharmaceutical composition designed for the oral administration of progesterone to individuals in need of such treatment. The composition includes progesterone, a solubilizing agent predominantly consisting of C6-C12 fatty acid tri-esters of glycerol, and a nonionic surfactant, specifically lauroyl polyoxyl-32 glycerides. The progesterone content in the composition ranges from 20 to 50 weight percent, with options for specific dosages between 25 mg to 200 mg, including 75 mg or 150 mg variants.

Furthermore, the patent details additional components and specifications of the pharmaceutical composition, such as the inclusion of a C6-C12 fatty acid mono-ester of glycerol in the solubilizing agent, the presence of solubilized and suspended progesterone, and the option for encapsulation in a gelatin capsule. The total mass of the composition is specified to be less than 500 mg, with a breakdown of the composition's components by weight. Additionally, the composition may include an antioxidant, specifically butylated hydroxy toluene, and may feature medium chain triglycerides of caprylic and capric fatty acids in the solubilizing agent. These detailed claims provide a comprehensive overview of the unique pharmaceutical composition designed for the effective oral administration of progesterone to individuals in need of such treatment.

To know more about GlobalData’s detailed insights on TherapeuticsMD, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies